GT Biopharma (GTBP) Cash from Investing Activities (2017 - 2024)
GT Biopharma (GTBP) posted quarterly Cash from Investing Activities of $1000.0 for Q4 2024, down 99.79% year-over-year from $478000.0 in Q1 2024, and up 200.0% quarter-over-quarter from -$1000.0 in Q3 2024.
GT Biopharma (GTBP) Cash from Investing Activities (2017 - 2024) Analysis & Trends
GT Biopharma (GTBP) has reported Cash from Investing Activities for 7 consecutive years, with $1000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Cash from Investing Activities fell 99.79% year-over-year to $1000.0; the TTM figure through Dec 2024 stood at $12.9 million (up 741.76% YoY), while the FY2024 annual figure was $12.9 million, up 741.76% from the prior year.
- Cash from Investing Activities rose to $1000.0 in Q4 2024 per GTBP's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $7.9 million in Q2 2024 and bottomed at -$7.0 million in Q1 2023.
- Historically, Cash from Investing Activities has averaged $2.0 million across 4 years, with a median of $1.8 million in 2023.
- On a YoY basis, Cash from Investing Activities climbed as much as 7280.0% in 2023 and fell as far as 297.82% in 2023.
- GT Biopharma's Cash from Investing Activities stood at $3.0 million in 2021, then jumped by 150.95% to $7.5 million in 2022, then plunged by 93.63% to $478000.0 in 2023, then slumped by 99.79% to $1000.0 in 2024.
- Business Quant data shows GTBP's Cash from Investing Activities at $1000.0 in Q4 2024, -$1000.0 in Q3 2024, and $7.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | 7.86 Mn |
| Jun 30, 2024 | 7.86 Mn |
| Mar 31, 2024 | 5.03 Mn |
| Mar 31, 2024 | 5.03 Mn |
| Dec 31, 2023 | 478,000.00 |
| Dec 31, 2023 | 478,000.00 |
| Sep 30, 2023 | 1.85 Mn |
| Sep 30, 2023 | 1.85 Mn |
| Jun 30, 2023 | 2.66 Mn |
| Jun 30, 2023 | 2.66 Mn |
| Mar 31, 2023 | -6.99 Mn |
| Mar 31, 2023 | -6.99 Mn |
| Dec 31, 2022 | 7.51 Mn |
| Dec 31, 2022 | 7.51 Mn |
| Sep 30, 2022 | 25,000.00 |
| Sep 30, 2022 | 25,000.00 |